LON:POLB Poolbeg Pharma (POLB) Share Price, News & Analysis GBX 7.18 -0.17 (-2.31%) As of 12:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and Trends About Poolbeg Pharma Stock (LON:POLB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Poolbeg Pharma alerts:Sign Up Key Stats Today's Range 6.90▼ 7.5050-Day Range 6.14▼ 9.3052-Week Range 3.30▼ 9.30Volume1.12 million shsAverage Volume2.09 million shsMarket Capitalization£54.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs. Read More Receive POLB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Poolbeg Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. POLB Stock News HeadlinesPoolbeg Pharma retains ‘buy’ rating at Cavendish after safety review allows trial to continueSeptember 29 at 10:02 AM | uk.finance.yahoo.comPoolbeg Pharma funded to finish both trials as it courts partners for cancer drugSeptember 29 at 10:02 AM | uk.finance.yahoo.comMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 13 years, with an average gain close to 19%. And this year may be setting up better than most. Bitcoin just strung together its first positive August and September since at least 2013. Historically, when September finished green, October followed with a gain four times out of five. History isn't a guarantee. But I pay attention when the calendar and the momentum line up.October 2 at 1:00 AM | Crypto 101 Media (Ad)Poolbeg Pharma (LON:POLB) Posts Quarterly Earnings ResultsSeptember 29 at 7:56 AM | americanbankingnews.comPoolbeg Pharma doses eight patients in cancer side-effect trialSeptember 28, 2026 | uk.finance.yahoo.comInterim data from POLB 001 TOPICAL clinical trialSeptember 25, 2026 | markets.ft.comIrish biotech's cancer drug trial cleared to continueSeptember 25, 2026 | msn.comPoolbeg Pharma gets green light to continue clinical trialSeptember 25, 2026 | uk.finance.yahoo.comSee More Headlines POLB Stock Analysis - Frequently Asked Questions How have POLB shares performed this year? Poolbeg Pharma's stock was trading at GBX 4 at the start of the year. Since then, POLB stock has increased by 82.5% and is now trading at GBX 7.30. How were Poolbeg Pharma's earnings last quarter? Poolbeg Pharma PLC (LON:POLB) released its earnings results on Tuesday, September, 29th. The company reported ($0.28) earnings per share (EPS) for the quarter. How do I buy shares of Poolbeg Pharma? Shares of POLB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Poolbeg Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Poolbeg Pharma investors own include EQTEC (EQT), Great Western Mining (GWMO), Power Metal Resources (POW), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), Alzamend Neuro (ALZN) and Alpine 4 (ALPP). Company Calendar Last Earnings9/29/2026Today10/02/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:POLB CIKN/A Webwww.poolbegpharma.com Phone44 20 7183 1499FaxN/AEmployees12Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£4.50 billion Net MarginsN/A Pretax MarginN/A Return on Equity-71.28% Return on Assets-21.33% Debt Debt-to-Equity RatioN/A Current Ratio12.44 Quick Ratio47.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 3.41 per share Price / Cash Flow2.11 Book ValueGBX 2,489.80 per share Price / Book0.00Miscellaneous Outstanding Shares763,437,000Free FloatN/AMarket Cap£54.81 million OptionableNot Optionable Beta1.83 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (LON:POLB) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredTrump's crypto bank just got approvedHere's a detail almost everyone missed about last October. When crypto stumbled in October 2025, Trump's cr...Crypto 101 Media | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThe rich already moved their moneyBy the time a crash hits the news, it's already too late to protect your money. Parkview Capital's free Mar...Parkview Capital Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredThe SEC Just Opened The Floodgates…The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poolbeg Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Poolbeg Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
